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Abstract
Introduction: Cystinosis is a rare metabolic genetic disorder caused by a mutation in the cystinosin lysosomal
cystine transporter gene. Clinically, it is characterized by systemic accumulation of cystine crystals in tissues causing
end-organ dysfunction in the kidney, eyes, muscles, and other organs in the body. In very rare cases, it can also
involve the bone marrow and the resulting cystine crystal deposition can cause myelosuppression leading to
pancytopenia.
Case presentation: Here we report the case of a 26-year-old white woman with cystinosis and other complex
medical comorbidities who developed pancytopenia. She was worked up extensively and ruled out for common
causes of pancytopenia (infectious disorders, vitamin deficiencies secondary to gastrointestinal malabsorption,
rheumatologic, and hematologic disorders). On bone marrow biopsy she was found to have extensive deposits of
cystine crystals, which was thought to be the cause of her myelosuppression leading to her pancytopenia. As a result,
by treating her underlying cystinosis more aggressively we were able to observe an improvement in her pancytopenia
a few months afterwards.
Conclusions: Pancytopenia secondary to myelosuppression from cystine crystal deposition in the bone marrow is a
very rare complication that has been reported in only a handful of case reports. This case illustrates the importance of
keeping a broad differential diagnosis and systematically ruling out common causes of pancytopenia. It also
demonstrates the importance of bone marrow biopsies in the evaluation of unexplained pancytopenia.
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Introduction
Cystinosis is a rare metabolic genetic disorder caused by a
mutation in the cystinosin lysosomal cystine transporter
(CTNS) gene characterized by an accumulation of cystine
crystals in the tissues causing end-organ damage [1, 2].
This gene has been mapped to chromosome 17p13 [2]. It
consists of 12 exons and encodes for 367 amino acids with
a 65kb deletion being the most common gene mutation
amongst these patients [2]. A study done in France, esti-
mated that it affected 1 in 100,000 to 200,000 children
worldwide at birth [3]. These patients most often develop
end-organ dysfunction of the kidneys, eyes, and endocrine
system with a mean life expectancy of 28.5 years [1, 3]. In
rare cases patients will also develop complications of pan-
cytopenia secondary to bone marrow suppression from
cystine crystal deposition [4–9]. Here we report a rare case
of pancytopenia in a patient with cystinosis secondary to
myelosuppression from cystine crystal deposition.
Case presentation
A 26-year-old white woman with hereditary cystinosis
and multiple medical comorbidities was referred to us
for newly developed pancytopenia. At 13 months she
presented with nausea, vomiting, failure to thrive, and
renal failure and required in-patient hospitalization.
During this initial work up she was found to have her-
editary cystinosis by detecting elevated levels of cystine
in her peripheral blood leukocytes. It was determined
that her cystinosis caused her to develop a secondary
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renal Fanconi’s syndrome, which had led to the symptoms
of nausea, vomiting, failure to thrive, and renal failure. As
a result, she was then started on cysteamine treatment as
a young child. She then progressively developed worsening
nephropathy secondary to her cystinosis and underwent a
renal transplant at age 16. Three years later she unfortu-
nately developed rejection of her transplanted kidney and
required a nephrectomy. She was then put on chronic
hemodialysis for end-stage renal disease (ESRD) three
times a week. Due to her ESRD she developed chronic
anemia secondary to chronic kidney disease (CKD). She
eventually required several blood transfusions and had to
be placed on weekly injections of erythropoietin. Over the
next 4 years she then developed other medical conditions
such as hypertension, hypothyroidism, esophagitis with
esophageal ulceration status post-Nissen fundoplication,
gastric outlet obstruction status post-Roux-en-Y surgery,
and multiple deep vein thromboses requiring chronic
anticoagulation with Coumadin (warfarin). Later she de-
veloped thrombocytopenia with platelets fluctuating be-
tween 40×103/μl and 80×103/μl. She was then referred to
our clinic for a consult after a recent hospitalization found
her to be pancytopenic with leukopenia, anemia, and
thrombocytopenia.
At the time of the consult, she had stable vital signs
and no clinical signs of bleeding. She denied any
hematuria, melena, blood in her stools, or vaginal
bleeding. Her physical examination was unremarkable
with no signs of ecchymosis or contusions. Her
complete blood count (CBC) showed white blood cell
(WBC) count was 1.7×103/μl with an absolute neutro-
phil count of 714/μl, a hemoglobin level of 10.0g/dl,
hematocrit of 29.8%, and a platelet count of 38×103/μl.
Her mean corpuscular volume (MCV) was 84.8fl (nor-
mal range, 81.5 to 97.0fl). Her reticulocyte count was
2.4% (normal range, 0.9 to 2.5%) with a reticulocyte
index of 1.18. Her vitamin B12 was 1298pg/ml (normal
range, 180 to 1241pg/ml) and folate 8.9ng/ml (3.0 to
18.2ng/ml). She was taking Coumadin (warfarin) due to
a history of recurrent deep vein thrombosis (DVT) so
her prothrombin time and international normalized ra-
tio (INR) were elevated at 28.2 seconds (normal range,
10.0 to 11.3 seconds) and 2.74 (target range, 2.0 to 3.0
for DVT treatment) respectively. She had been receiv-
ing erythropoietin for her anemia secondary to CKD so
it was not measured. Her hepatitis B and C, parvovirus
B16, and human immunodeficiency virus (HIV) assays
were all negative. Her Epstein–Barr virus (EBV) anti-
body titers were positive but she did not have clinical
signs of active mononucleosis such as fatigue, myalgia,
fever, or sore throat. We then performed a peripheral
blood smear which found her red blood cells (RBCs) to
be hypochromatic and normocytic. Polychromasia was
not increased while her WBCs and platelets were
moderately decreased in numbers but normal in ap-
pearance. No circulating blasts or abnormal cells were
visualized.
We then performed a bone marrow biopsy. The bone
marrow biopsy showed that the cellularity was 5% with ac-
tive trilineage hematopoiesis with only a moderate amount
of fat and stroma present. No circulating blasts or abnor-
mal cells were visualized in the bone marrow biopsy aspir-
ate or core. No immature cells were visualized and the
myeloid to erythroid ratio was estimated to be 3 to 4:1.
The megakaryocytes that were visualized appeared to be
normal in appearance. The quantity of observed megakar-
yocytes were found to be decreased but adequate in num-
ber when one accounted for the overall panhypoplasia
present in the examined biopsy specimen. Flow cytometry
revealed no abnormalities and iron staining revealed in-
creased iron stores. However, much to our surprise there
were extensive sheets of deposits of rhomboid and rect-
angular shaped, birefringent cystine crystals visualized
under polarized light, which occupied about 30% of the
marrow components (Fig. 1). Since other causes of pan-
cytopenia had been ruled out (infectious, gastrointestinal
malabsorption, rheumatologic, and hematologic disorders),
we were left with the most likely possibility being that she
had myelosuppression/marrow replacement from depos-
ition of cystine crystals as the cause of her pancytopenia.
On further interview the patient revealed that she had been
having difficulty taking her cysteamine on a consistent
basis for the past few months due to multiple hospitaliza-
tions for other medical reasons. After our consultation, her
medical condition remained stable for the next few months
without any prolonged hospitalizations and she was able to
continue her out-patient cysteamine treatment with min-
imal interruptions. On our next follow-up visit we ob-
served an improvement in her thrombocytopenia with
platelets increasing from 38×103/μl to 60×103/μl over the
course of the next few months. Unfortunately, during the
course of the next 2 years she had repeated hospital admis-
sions for other medical problems and had much difficulty
again maintaining consistent cysteamine treatment. Her
Fig. 1 Bone marrow core and aspirate smear. Numerous rhomboid
and rectangular shaped, birefringent cystine crystals are visualized
under polarized light. a Sheets of histiocytes with refractile cystine
crystals seen in the core biopsy (hematoxylin and eosin stain, ×400).
b A single histiocyte contains multiple refractile rhomboid/
rectangular crystals in the cytoplasm (Giemsa stain, ×1000)
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thrombocytopenia worsened again to about 30×103/μl. A
repeat bone marrow biopsy was done (about 3 years after
the initial bone marrow biopsy) and showed increased de-
posits of cystine crystals making up approximately 40% of
her bone marrow components.
Discussion
Here we present an adult patient with cystinosis who de-
veloped bone marrow suppression secondary to cystine
crystal deposition. In cystinosis, the initial presenting
symptoms occur approximately at 6 to 12 months of age
with renal Fanconi’s syndrome, which is secondary to ac-
cumulation of cystine crystals in the kidneys causing prox-
imal renal tubule damage [1, 10]. These patients develop
dysfunction in the proximal renal tubules and are unable
to reabsorb solutes [1, 10]. This leads to excessive urinary
loss of protein, glucose, amino acids, phosphate, calcium,
magnesium, sodium, potassium, bicarbonate, carnitine,
and water [1, 10]. As a result these patients will clinically
present with polyuria, polydipsia, electrolyte imbalance,
dehydration, rickets, and growth failure if untreated as an
infant [1, 10]. Prior to the 1970s cystinosis used to be a
universally fatal pediatric disease due to renal failure sec-
ondary to renal Fanconi’s syndrome [1]. However, with the
development of renal transplantation and cysteamine
treatment this disease has been transformed into a chronic
adult disease with multiorgan involvement [11]. Renal
transplantation was first successfully performed in these
patients in 1977 and has become widespread since then
[11]. Around this time, cysteamine (beta-mercaptoethyla-
mine) was found to deplete cultured cystinotic skin fibro-
blasts of cystine and has now become the standard of care
[1]. Cysteamine works by reacting with cystine trapped in
the lysosome and forms a mixed disulfide bond which al-
lows it to exit the lysosome via the lysine (cationic) trans-
port system [12]. However, cysteamine has many adverse
effects including gastrointestinal toxicities such as nausea,
vomiting, diarrhea, and a noxious rotten-egg odor and a
taste that makes compliance very difficult [13]. In fact this
drug’s gastrointestinal toxicities have been used as a model
system to induce duodenal ulcers in rats for researchers
[14]. Patients that manage to tolerate chronic cysteamine
treatment have been observed to have a mean life expect-
ancy of 28.5 years [1]. During their adult years, these pa-
tients have been found to develop extrarenal systemic
involvement with end-organ damage in the eyes, muscles,
central nervous system, and endocrine system [1]. Only in
rare cases has it been observed to involve the bone mar-
row and cause clinical symptoms [4–9].
At the time of this publication a literature review shows
only a handful of case reports describing pancytopenia in
patients with cystinosis [4–9]. Pancytopenia is a medical
condition with a large differential diagnosis that encom-
passes many different organ systems. It can be caused by
various etiologies such as vitamin deficiencies secondary
to gastrointestinal malabsorption, rheumatologic, infec-
tious, and hematologic diseases. The cause is often multi-
factorial and requires a systematic work up in order to
determine the root cause. In our patient she had a compli-
cated medical history with many medical comorbidities
encompassing multiple organ systems. This required us to
perform a comprehensive work up to rule out common
causes of secondary pancytopenia (infectious, vitamin de-
ficiencies secondary to gastrointestinal malabsorption,
rheumatologic, hematologic) as discussed in the Case
presentation section.
As for possible hematologic diseases which could
cause pancytopenia, the differential diagnosis in this
patient included congenital and acquired disorders. For
congenital disorders the differential diagnosis included
Fanconi anemia, dyskeratosis congenita, Shwachman–
Diamond syndrome, and congenital amegakaryocytic
thrombocytopenia [15]. These diseases normally
present in the early years of childhood before 10
years of age [15]. Fanconi anemia is an autosomal re-
cessive or X-linked disorder with median age of pres-
entation from 6- to 9-years old [15]. In addition,
patients with pancytopenia often have clinical charac-
teristics of short stature, hypopigmented and café-au-
lait spots, abnormality of the thumbs, microcephaly
or hydrocephaly, hypogonadism, and developmental
delay [15]. Dyskeratosis congenita is characterized by
bone marrow failure, cancer predisposition, and clin-
ical characteristics demonstrating ectodermal dysplasia
[15]. Classically, these patients were recognized with a
triad of: 1) mottled skin hyperpigmentation of the
face, neck, shoulders, and trunk, 2) nail dystrophy
present bilaterally in the hands and feet, and 3) mu-
cosal leukoplakia [15]. Approximately 70% of these
patients will have one of the above physical examin-
ation findings [15]. Shwachman–Diamond syndrome
usually presents in infancy and is characterized by
exocrine pancreatic dysfunction, bone marrow failure,
and skeletal abnormalities such as osteopenia leading
to pathologic fractures [15]. Congenital amegakaryocy-
tic thrombocytopenia is characterized by isolated
thrombocytopenia in infancy with absent or a significantly
reduced number of megakaryocytes out of proportion to
the overall cellularity seen on bone marrow biopsy [15].
These patients are also noted to have none of the physical
characteristics or birth defects associated with other inher-
ited bone marrow failure syndromes [15]. As mentioned
in the Case presentation section, our patient presented
with pancytopenia at the age of 26 and she did not have
any of the physical examination findings characteristic of
the various congenital bone marrow failure syndromes.
Furthermore, her bone marrow biopsy showed megakar-
yocytes which were present and not significantly reduced
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when considering the overall hypocellularity of the exam-
ined specimen. As a result we were able to conclude that
her pancytopenia was very unlikely to be caused by one of
the above congenital hematological disorders.
For acquired hematological disorders which could cause
pancytopenia the differential diagnosis includes aplastic
anemia, hematologic malignancies, and myelodysplastic
syndrome. Aplastic anemia is characterized by diminished
or absent hematopoietic precursors in the bone marrow,
most often due to injury to the hematopoietic stem cells
from primary or secondary causes. It is commonly a diag-
nosis of exclusion with bone marrow biopsy showing: 1)
profound hypocellularity with decrease in all cellular line-
ages and an empty marrow composed mostly of fat cells
and stroma, 2) no presence of infiltration from malignant
cells or fibrosis, and 3) morphologically normal residual
hematopoietic cells and hematopoiesis which is not meg-
aloblastic. As mentioned above, our patient’s bone marrow
biopsy did not show any immature or abnormal cells seen
in hematological malignancies. Although the marrow was
profoundly hypocellular in this patient, it did not appear to
have a significantly increased deposition of fat cells or
stroma as seen in aplastic anemia. In fact it appeared that a
significant amount of marrow space (30% of the examined
specimen) was replaced with the rhomboid and rectangular
shaped, birefringent cystine crystals (Fig. 1). Therefore,
these findings made it most likely that our patient’s pan-
cytopenia was primarily due to myelosuppression second-
ary to bone marrow replacement from deposition of
cystine crystals. However, we acknowledge that since aplas-
tic anemia is a diagnosis of exclusion with no clinically
available specific test to rule it in or out we cannot exclude
the possibility that the patient may also have an additional
underlying superimposed aplastic anemia.
Conclusions
In conclusion, pancytopenia secondary to myelosuppres-
sion from cystine crystal deposition in the bone marrow is
a very rare complication. This case illustrates the import-
ance of keeping a broad differential diagnosis and system-
atically ruling out common causes of pancytopenia. It also
demonstrates the importance of bone marrow biopsies in
the evaluation of unexplained pancytopenia.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for re-
view by the Editor-in-Chief of this journal.
Abbreviations
CKD: chronic kidney disease; DVT: deep vein thrombosis; ESRD: end-stage
renal disease; WBC: white blood cell.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
YL was the primary author documenting the patient’s care and composing the
case report. CN is the attending hematologist who follows the patient regularly
as an out-patient and contributed to the editing of the manuscript. XZ was
responsible for reviewing the pathology, which led to the final diagnosis and
providing the image for the figure in the manuscript. She was also involved in
the editing process of this manuscript. All authors have read and approved the
final version of this manuscript.
Author details
1Department of Medicine, Division of Hematology Oncology, University of
California Irvine Medical Center, 101 The City Drive South, Orange, CA 92868,
USA. 2Department of Pathology, University of California Irvine Medical
Center, 101 The City Drive South, Orange, CA 92868, USA.
Received: 10 February 2015 Accepted: 21 August 2015
References
1. Gahl WA, Thoene JG, Schneider JA. Cystinosis. N Engl J Med.
2002;347(2):111–21.
2. Town M, Jean G, Cherqui S, Attard M, Forestier L, Whitmore SA, et al.
A novel gene encoding an integral membrane protein is mutated in
nephropathic cystinosis. Nat Genet. 1998;18(4):319–24.
3. Bois E, Feingold J, Frenay P, Briard ML. Infantile cystinosis in France:
genetics, incidence, geographic distribution. J Med Genet. 1976;13(6):434–8.
4. Abdulsalam AH, Khamis MH, Bain BJ. Diagnosis of cystinosis from a bone
marrow aspirate. Am J Hematol. 2013;88(2):151.
5. Bigley V, Bhartia S, Wood A. Nephropathic cystinosis with bone marrow
involvement. Br J Haematol. 2007;136(2):180.
6. Busuttil DP, Liu Yin JA. The bone marrow in hereditary cystinosis.
Br J Haematol. 2000;111(2):385.
7. Emadi A, Burns KH, Confer B, Borowitz MJ, Streiff MB. Hematological
manifestations of nephropathic cystinosis. Acta Haematol. 2008;119(3):169–72.
8. Ercin C, Paksoy N, Gok ND. Hereditary cystinosis detected by CD68 staining
of the bone marrow biopsies of 2 siblings. Appl Immunohistochem Mol
Morphol. Epub 2014 Aug 22. PubMed.
9. Quinn JP, Royston D, Murphy PT. Bone marrow findings in hereditary
cystinosis with renal failure. Am J Hematol. 2004;76(1):79.
10. Broyer M, Tete MJ, Gubler MC. Late symptoms in infantile cystinosis.
Pediatr Nephrol. 1987;1(3):519–24.
11. Malekzadeh MH, Neustein HB, Schneider JA, Pennisi AJ, Ettenger RB,
Uittenbogaart CH, et al. Cadaver renal transplantation in children with
cystinosis. Am J Med. 1977;63(4):525–33.
12. Thoene JG, Oshima RG, Ritchie DG, Schneider JA. Cystinotic fibroblasts
accumulate cystine from intracellular protein degradation. Proc Natl Acad
Sci U S A. 1977;74(10):4505–7.
13. Schneider JA. Treatment of cystinosis: simple in principle, difficult in
practice. J Pediatr. 2004;145(4):436–8.
14. Szabo S, Cho CH. From cysteamine to MPTP: structure-activity studies with
duodenal ulcerogens. Toxicol Pathol. 1988;16(2):205–12.
15. Shimamura A, Alter BP. Pathophysiology and management of inherited
bone marrow failure syndromes. Blood Rev. 2010;24(3):101–22.
Lyou et al. Journal of Medical Case Reports  (2015) 9:205 Page 4 of 4
